Peloton Therapeutics, Inc.
Oral small-molecule therapeutic drugs targeting cancer and serious diseases
- Sector
- Biotech
- Headquarters
- DALLAS, TX
- Founded
- 2010
- Latest Form D
- $2M, Jul 2011
- Total capital
- $2M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $2M
- 1 Form D · last Jul 2011
- 184 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 18
- 22 pending · first 2017
- Rank in peer group#94 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#94 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- John JoseyResearcherExecutive OfficerLinked by 1 patent
- Brett RingleDirectorNamed in SEC Form D filings
- David GoeddelDirectorNamed in SEC Form D filings
- John CreecyDirectorNamed in SEC Form D filings
- Michael BrownDirectorNamed in SEC Form D filings
- Tim KutzkeyExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 18 granted of 40- PendingPyrazolesulfonamides As Antitumor AgentsUSPTOApplication 19304725
- PendingSolid Dispersions And Pharmaceutical Compositions Comprising A Substituted Indane And Methods For The Preparation And Use ThereofUSPTOApplication 19254916
- GrantedSolid Dispersions And Pharmaceutical Compositions Comprising A Substituted Indane And Methods For The Preparation And Use ThereofUSPTOUS 12,358,870
Show all 40 patent records
- Pyrazolesulfonamides As Antitumor AgentsDec 4, 2025 · Application 19304725Pending
- Solid Dispersions And Pharmaceutical Compositions Comprising A Substituted Indane And Methods For The Preparation And Use ThereofOct 23, 2025 · Application 19254916Pending
- Solid Dispersions And Pharmaceutical Compositions Comprising A Substituted Indane And Methods For The Preparation And Use ThereofJul 15, 2025 · US 12,358,870Granted
- Compositions And Methods For Inhibiting CD73Jun 17, 2025 · US 12,331,068Granted
- Tricyclic Sultams And Sulfamides As Antitumor AgentsSep 5, 2024 · Application 18681173Pending
- Aryl Ethers And Uses ThereofApr 30, 2024 · US RE49,948Granted
- CD73 Inhibitors And Uses ThereofFeb 28, 2023 · US 11,591,355Granted
- Methods Of Preparing Substituted IndanesMar 17, 2022 · Application 17017864Pending
- Methods Of Reducing Inflammation Of The Digestive System With Inhibitors Of HIF-2- AlphaJan 21, 2021 · Application 16980648Pending
- Aromatic Compounds And Uses ThereofOct 20, 2020 · US 10,807,948Granted
- Combination Therapy Of A HIF-2-ALPHA Inhibitor And An Immunotherapeutic Agent And Uses ThereofSep 29, 2020 · US 10,786,480Granted
- Aryl Ethers And Uses ThereofJun 18, 2020 · Application 16795697Pending
- CD73 Inhibitors And Uses ThereofApr 16, 2020 · Application 16498338Pending
- Aryl Ethers And Uses ThereofMar 24, 2020 · US 10,597,366Granted
- Compositions For Use In Treating GlioblastomaDec 24, 2019 · US 10,512,626Granted
- Combination Therapy Of A HIF-2-ALPHA Inhibitor And An Immunotherapeutic Agent And Uses ThereofJul 2, 2019 · US 10,335,388Granted
- Compositions For Use In Treating Pulmonary Arterial HypertensionMay 7, 2019 · US 10,278,942Granted
- Compositions for Use in Treating Pulmonary Arterial HypertensionJan 17, 2019 · Application 16036291Pending
- Substituted Pyridines And Uses ThereofDec 18, 2018 · US 10,155,726Granted
- Aryl Ethers And Uses ThereofDec 4, 2018 · US 10,144,711Granted
- Benzimidazole Derivatives And Uses ThereofAug 7, 2018 · US 10,040,767Granted
- Aryl Ethers And Uses ThereofMay 15, 2018 · US 9,969,689Granted
- Aryl Ethers And Uses ThereofMar 6, 2018 · US 9,908,845Granted
- HIF-2-ALPHA Inhibitor PolymorphsFeb 22, 2018 · Application 15556248Pending
- Aryl Ethers And Uses ThereofFeb 20, 2018 · US 9,896,418Granted
- Cyclic Sulfone And Sulfoximine Analogs And Uses ThereofFeb 6, 2018 · US 9,884,843Granted
- Tricyclic Inhibitors Of HIF-2-ALPHA And Uses ThereofOct 24, 2017 · US 9,796,697Granted
- Pyrazolesulfonamides As Antitumor AgentsApplication 62832125Pending
- Compositions And Methods For Inhibiting CD73Application PCTUS2019034826Pending
- Solid Dispersions And Pharmaceutical Compositions Comprising A Substituted Indane And Methods For The Preparation And Use ThereofApplication PCTUS2019057725Pending
- Pyrazolesulfonamides As Antitumor AgentsApplication PCTUS2020026799Pending
- Tricyclic Sultams And Sulfamides As Antitumor AgentsApplication 63254566Pending
- Tricyclic Sultams And Sulfamides As Antitumor AgentsApplication PCTUS2022043437Pending
- Inhibitors Of CD73 And Uses ThereofApplication 62526265Pending
- CD73 Inhibitors And Uses ThereofApplication 62480093Pending
- N-biaryl Sulfonamides As Modulators Of The Hippo PathwayApplication 63560203Pending
- Combination Therapy Of A HIF-2-ALPHA Inhibitor And An Immunotherapeutic Agent And Uses ThereofApplication PCTUS2016027611Pending
- HIF-2-ALPHA Inhibitor PolymorphsApplication PCTUS2016021846Pending
- Compositions For Use In Treating Pulmonary Arterial HypertensionApplication PCTUS2016021492Pending
- Substituted Pyridines And Uses ThereofApplication PCTUS2016021061Pending
Related companies, and why
- IMMUNOCHEM THERAPEUTICS LLCSimilar federal contract value in Biotech · null in contracts
- Alloplex Biotherapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Xenagos Bio, Inc.Similar federal contract value in Biotech · null in contracts
- OWIC TECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts
- Beech Tree Labs, Inc.Similar federal contract value in Biotech · null in contracts
- TRIO PHARMACEUTICALS INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .